State Initiatives

Veto Illinois HB 1780 Which Puts Patient Access to Generic Medicines at Risk

The State of Illinois is considering legislation (HB 1780) to establish a statewide drug take back program funded almost exclusively by generic drug manufacturers. HB 1780, as currently drafted, would disproportionately impact the makers of low-cost generic medicines instead of the manufacturers of high-cost brand-name drugs. Generic medicines account for less than 2% of health care spending. Yet although generic manufacturers only generate a small fraction of the revenue of brand-name drug companies, generic companies will be forced to foot the bill.

State of the Union: Generic and Biosimilar Savings for States and Taxpayers

According to the latest U.S. Generic and Biosimilar Medicines Savings Report, Americans who took generics and biosimilars saved $338 billion in health care costs in 2020 and nearly $2.4 trillion in the last decade. These medicines provide budgetary relief throughout the U.S. health care system, and taxpayers in all 50 states benefit from the savings generated for Medicare and Medicaid enrollees. On average, states saved $6.6 billion from the use of generics and biosimilars in 2020.

AAM Statement on Maine LD 1117

WASHINGTON DC (June 16, 2021) – “The Association for Accessible Medicines (AAM) strongly encourages the Maine House of Representatives to oppose LD 1117. The fact is generic medicines drive cost savings for patients and increase access to life-saving treatments. According to the Maine Health Data Organization, every one of the 25 most costly prescription drugs in the state is a brand-name drug – none are generic medicines. LD 1117 misdiagnoses the problem of high drug prices and instead would only result in harming patient access to affordable generic medicines.”

Lisa Steelman Joins AAM as Vice President, State Government Affairs

WASHINGTON, DC (August 10, 2020) — Today Lisa Steelman is joining the Association for Accessible Medicines (AAM). As Vice President, State Government Affairs, she serves as a senior strategist and lobbyist in partnership with the Senior Vice President, Government Affairs, Chris Bowlin, and other members of the State Government Affairs team to represent AAM and its member companies’ interests before state legislators, regulators and other state and local governmental entities.

A Generic Summer Savings Tour: How Did Your State Do?

The 11th edition of the Association for Accessible Medicines' annual Access and Savings Report (see summary) reveals how much money American patients and taxpayers saved in 2018 through competition from generic drugs and biosimilar alternatives to brand-name biologic medicines. The report provides data by state, based on findings by IQVIA. We’re releasing a detailed publication later this summer.

Some notable facts from the state data:

Subscribe to State Initiatives

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.